Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immuron Limited ( (AU:IMC) ) has provided an update.
Immuron Limited has issued 1,142,909 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant legal provisions. This issuance indicates the company’s adherence to regulatory requirements and suggests a strategic move to potentially enhance its financial position and operational capabilities.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases.
YTD Price Performance: -50.63%
Average Trading Volume: 1,056,012
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$12.68M
For detailed information about IMC stock, go to TipRanks’ Stock Analysis page.